LifeSci Capital analyst Cory Jubinville, PhD has maintained their bullish stance on CRNX stock, giving a Buy rating on October 23.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cory Jubinville, PhD has given his Buy rating due to a combination of factors related to Crinetics Pharmaceuticals’ promising developments in their neuroendocrine tumor (NET) pipeline. The company recently presented encouraging preliminary data on progression-free survival (PFS) for their drug paltusotine, which is in Phase 3 trials for carcinoid syndrome associated with NETs. This data, although preliminary and requiring cautious interpretation, suggests potential antiproliferative activity, which is a significant clinical endpoint in oncology.
Furthermore, the promising PFS signal enhances the clinical profile of paltusotine and sets the stage for more comprehensive assessments in the ongoing Phase 3 CAREFNDR trial. Despite the current analysis being unblinded and underpowered, the data provides an early indication of the drug’s potential efficacy. Additionally, Crinetics’ financial position, with approximately 3.2 years of cash runway, supports the continued development of their pipeline, contributing to the positive outlook and Buy rating by Cory Jubinville, PhD.